Finn
HALO Biotechnology · Drug delivery · Royalties · Profitable biotech · Thesis updated November 8, 2026

Record royalties drive growth while US patent battles persist

01 Running thesis

Royalties still have runway

Halozyme is a picks-and-shovels biotech. It does not need to build every drug itself. It licenses delivery technology to larger drug companies, then collects fees, milestones, and royalties when those partners succeed.

The core bull case gained more momentum in Q3 2026. Royalty revenue rose 44% year over year to a record $341 million. Management raised full-year guidance and added new ENHANZE target nominations from major partners like argenx and Johnson & Johnson. With 13 ENHANZE programs expected in the clinic by year-end, the company has plenty of future revenue drivers.

Capital returns are also in full swing. Halozyme is aggressively deploying its $1 billion buyback plan, which can lift per-share results if the core business keeps growing.

The bear case remains tied to litigation and early-stage platforms. While Halozyme secured a European injunction against Merck for patent infringement, US appeals will drag on until roughly 2028. Furthermore, investors still need proof that newer platforms like Hypercon and Aerocon can become commercial royalty machines.

Nov 2026▲Q3 2026 earnings highlighted 44% YoY royalty growth to a record $341 million and a raised financial guidance. A Dutch Patent Court rejected Merck's invalidity challenges, securing a win for Halozyme in Europe.
Aug 2026▲Q2 2026 earnings showed royalty revenue growing 50% year over year to $308 million. Halozyme also signed new ENHANZE agreements, expanding into new modalities like nucleic acids and ADCs.
Aug 2026▼The Q2 2026 10-Q flagged a new proposed rule from CMS regarding the Medicare Drug Price Negotiations Program. This increases regulatory uncertainty for fixed-combination drugs for 2029 and beyond.
May 2026▲Q1 2026 reaffirmed the ENHANZE growth story. Royalty revenue grew 43% year over year, guidance was reaffirmed, and management framed about 66% of projected royalties from current launched products as still ahead from 2026 to 2032.
May 2026▲Halozyme announced a $1 billion share repurchase program through 2028, with at least $400 million expected in 2026. That adds a clearer capital return path to the thesis.
May 2026▲New GSK, Vertex, and Oruka agreements strengthened the multi-platform story. GSK adds the first potential ENHANZE use in antibody-drug conjugates, while Vertex and Oruka add Hypercon validation.
May 2026▼The first Hypercon Phase I starts are now expected in the first half of 2027. That is a small timing pushout and keeps proof of the new platform in the future.
Feb 2026▲The 2025 10-K and Q4 update marked Halozyme's move from a mostly ENHANZE story to a three-platform drug delivery company. The same update sharpened the Merck patent case as a key legal overhang.
02 Business model

Licensing shots, not selling drugs

ENHANZE is Halozyme's main product platform. It uses rHuPH20, an enzyme that temporarily opens space under the skin so large drug doses can be injected under the skin instead of through a long IV infusion. Partners pay upfront fees, development and sales milestones, buy bulk rHuPH20, and pay royalties on approved products.

The best part of the model is operating leverage. Royalties can grow as partners sell more of their drugs, while Halozyme does not carry the full cost of large global sales teams for those drugs. Royalties remain the biggest revenue stream and continue to grow faster than total company revenue.

Product sales are the second stream. They include proprietary products like Hylenex and XYOSTED, bulk rHuPH20 sold to partners, and device-related product sales. This stream can jump around because partner ordering patterns can change from quarter to quarter.

Collaborative revenue is the lumpiest stream. It includes upfront fees and milestone payments tied to partner progress. Deals across new modalities add promise, but the exact economics are still partly unknown.

03 Product portfolio

What Halozyme owns

Growth engine

ENHANZE

The core drug delivery platform. It powers ten commercial partner products and remains the main source of royalty growth.

Cash cow

DARZALEX FASPRO and DARZALEX SC

Janssen's multiple myeloma franchise is Halozyme's largest disclosed royalty driver.

Growth engine

VYVGART Hytrulo

argenx's autoimmune drug is a fast-growing ENHANZE product that continues to see rapid sales adoption.

Steady

Phesgo

Roche's breast cancer product adds another large ENHANZE royalty stream. It continues to grow as a reliable contributor.

Option

Hypercon

Hypercon is a high-concentration drug delivery platform from the Elektrofi acquisition. Vertex and Oruka are partners, but Phase I starts are expected in the first half of 2027.

Option

Aerocon

Formerly known as Surf Bio, Aerocon is another high-concentration platform. It extends the long-term platform story but still needs clearer clinical timing.

Steady

Hylenex and XYOSTED

These are Halozyme's own marketed products. They help diversify revenue, but the company page story is mostly about partner royalties.

04 Business segments

Revenue mix

Royalties69%growing fast
Product sales, net30%modest
Revenues under collaborative agreements1%flat

Mix is based on Q3 2026 total revenue of $493 million. Royalties make up the vast majority of current sales, reaching $341 million in the quarter.

05 Risk factors

What could break the thesis

Merck patent case stretches in the US

High impact · Medium odds

Halozyme won a Dutch Patent Court injunction against Merck over alleged use of MDASE technology in subcutaneous Keytruda. However, adverse validity decisions on US patents mean the appeals process will persist into 2028, creating long-term uncertainty.

We watchPTAB rulings, US court updates, and European supply chain impacts on Merck.

Partner sales slow down

High impact · Medium odds

Halozyme depends on partners such as Janssen, argenx, and Roche to sell the drugs that generate royalties. If DARZALEX SC, VYVGART Hytrulo, or Phesgo slow, Halozyme cannot fix that by hiring its own sales force.

We watchQuarterly royalty growth, especially for DARZALEX, VYVGART Hytrulo, and newer launches.

Hypercon and Aerocon do not scale

Medium impact · Medium odds

The company guided the first Phase I clinical studies for Hypercon to start in the first half of 2027. Commercial proof for these newer platforms is years away.

We watchDisclosure of Hypercon Phase I asset progress and deal terms on future partnerships.

Supply chain bottlenecks

Medium impact · Low odds

Halozyme relies on a limited number of third-party manufacturers for bulk rHuPH20 and other key components. If supply misses partner needs, product sales and partner launches could be delayed.

We watchManagement comments on bulk rHuPH20 capacity and partner ordering patterns.

IRA policy changes after 2028

Medium impact · Low odds

CMS proposed rules for the Medicare Drug Price Negotiations Program could impact price negotiations for 2029 and beyond, affecting long-term ENHANZE royalty streams.

We watchCMS final guidance for future Medicare price negotiation cycles, especially rules for fixed-combination drugs.
06 Quick answers

In one breath

What does Halozyme actually do?

Halozyme licenses drug delivery technology to other drug companies. Its main platform, ENHANZE, helps some medicines move from IV infusion to faster under-the-skin injection.

Why are royalties so important for HALO?

Royalties are Halozyme's largest and fastest-growing revenue stream. In Q3 2026, royalty revenue rose 44% year over year to a record $341 million.

What is the Merck lawsuit about?

Halozyme says Merck used its patented subcutaneous delivery technology in the development of subcutaneous Keytruda. Halozyme won an injunction in Europe, but US appeals are ongoing.

Is Halozyme only an ENHANZE company?

ENHANZE is still the main value driver. Halozyme is also building Hypercon and Aerocon, two high-concentration delivery platforms, but those platforms still need clinical starts and commercial proof.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Halozyme Q3 2026 earnings call transcript
  2. Halozyme Q2 2026 Form 10-Q
  3. Halozyme Q1 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near Halozyme Therapeutics, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today